Confluence Wealth Services Inc. Raises Holdings in Abbott Laboratories $ABT

Confluence Wealth Services Inc. grew its holdings in Abbott Laboratories (NYSE:ABT) by 25.5% in the second quarter, Holdings Channel reports. The firm owned 44,422 shares of the healthcare product maker’s stock after buying an additional 9,031 shares during the quarter. Confluence Wealth Services Inc.’s holdings in Abbott Laboratories were worth $4,031,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ABT. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories in the 4th quarter worth about $25,000. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $26,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $114.16 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The firm has a fifty day moving average price of $99.51 and a 200-day moving average price of $99.93. The stock has a market cap of $197.54 billion, a PE ratio of 36.94, a price-to-earnings-growth ratio of 2.21 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now integrated into MiniMed’s Flex automated insulin-delivery system, which is commercially shipping in the United States. The partnership expands Abbott’s presence in the growing continuous glucose-monitoring and diabetes-care markets. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott entered a multiyear agreement with HealthTab to supply Afinion 2 analyzers for point-of-care HbA1c and lipid testing in UK pharmacies, supporting the Diagnostics segment and potential NHS-linked distribution. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Positive Sentiment: Analyst commentary continues to identify electrophysiology, continuous glucose-monitoring adoption and Abbott’s cardiovascular pipeline as important long-term growth drivers for the Medical Devices business. Abbott’s Medical Devices Growth Catalyst
• Neutral Sentiment: Recent commentary remains broadly constructive on Abbott’s long-term outlook, although one analysis characterized the stock as reasonably valued after its recent advance while another recommended a more cautious stance. This suggests valuation could limit near-term upside despite favorable operating trends.
• Negative Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims involving about 2,000 individuals concerning specialty formulas for premature infants. Although the company maintains that the products are safe and denies reliable evidence linking them to necrotizing enterocolitis, the settlement creates a substantial financial cost and keeps litigation risk in focus. Abbott Agrees to $670 Million Settlement
• Negative Sentiment: The company also settled an appeal related to a separate $495 million infant-formula verdict, reinforcing investor concerns about potential legal expenses and liabilities in the Nutrition business. Abbott Settles Appeal Over $495 Million Infant Formula Verdict

Analyst Ratings Changes

A number of brokerages recently weighed in on ABT. The Goldman Sachs Group lowered their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. UBS Group cut their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Robert W. Baird assumed coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Citigroup raised their price target on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $118.67.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.